A retrospective study for the impact of Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) for pre-exposure prophylaxis (PrEP)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 31 Jul 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Jul 2018 New trial record
27 Jul 2018 Results assessing impact of pre-exposure prophylaxis with Emtricitabine/tenofovir disoproxil fumarate on HIV diagnoses presented at the 22nd International AIDS Conference
24 Jul 2018 According to a Gilead Sciences media release, Conducted in collaboration with researchers at Emory University Rollins School of Public Health and the Centers for Disease Control and Prevention(CDC), Patrick Sullivan is a lead study author.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com